9.95

0.55% -0.02

Theravance Biopharma Inc (TBPH)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$9.97

Aprire:

$9.92

Volume 24 ore:

76,445

Relative Volume:

0.41

Capitalizzazione di mercato:

$484.87M

Reddito:

$62.02M

Utile/perdita netta:

$-45.65M

Rapporto P/E:

0.8759

EPS:

11.36

Flusso di cassa netto:

$-9.60M

1 W Prestazione:

+3.61%

1M Prestazione:

+14.49%

6M Prestazione:

+8.72%

1 anno Prestazione:

-3.55%

Intervallo 1D:

$9.74

$9.97

Intervallo di 1 settimana:

$9.25

$10.10

Portata 52W:

$7.44

$11.71

Theravance Biopharma Inc Stock (TBPH) Company Profile

Nome

Theravance Biopharma Inc

Settore

Healthcare (1195)

Industria

Biotechnology (683)

Telefono

650-808-6000

Indirizzo

UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN

Dipendente

Cinguettio

Prossima data di guadagno

2024-11-12

Ultimi documenti SEC

TBPH's Discussions on Twitter

Confronta TBPH con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
TBPH	9.95	484.87M	62.02M	-45.65M	-9.60M	11.36
VRTX	446.52	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	741.51	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	589.70	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	250.25	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	103.17	24.49B	3.30B	-501.07M	1.03B	11.54

Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2022-05-23	Iniziato	SVB Leerink	Outperform
2021-11-05	Aggiornamento	JP Morgan	Underweight → Neutral
2021-09-15	Downgrade	JP Morgan	Overweight → Underweight
2021-08-25	Downgrade	Morgan Stanley	Overweight → Underweight
2021-08-24	Downgrade	Cowen	Outperform → Market Perform
2020-10-14	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2020-07-07	Iniziato	JP Morgan	Overweight
2020-06-15	Iniziato	Morgan Stanley	Equal-Weight
2020-05-13	Iniziato	Cowen	Outperform
2020-01-08	Reiterato	H.C. Wainwright	Buy
2019-11-06	Aggiornamento	Robert W. Baird	Underperform → Neutral
2019-10-29	Iniziato	H.C. Wainwright	Buy
2018-03-29	Ripresa	Piper Jaffray	Overweight
2017-08-17	Iniziato	Evercore ISI	Outperform
2017-06-16	Iniziato	Cantor Fitzgerald	Overweight
2017-05-11	Reiterato	Needham	Buy
2016-12-21	Iniziato	Needham	Buy
2016-11-03	Iniziato	Piper Jaffray	Overweight
2016-10-12	Downgrade	Robert W. Baird	Neutral → Underperform
2016-08-03	Downgrade	BofA/Merrill	Neutral → Underperform
2016-06-20	Iniziato	Guggenheim	Buy
2016-06-20	Reiterato	Leerink Partners	Outperform
2016-05-12	Iniziato	Leerink Partners	Outperform
2016-05-05	Downgrade	BofA/Merrill	Buy → Neutral
2015-02-03	Aggiornamento	Robert W. Baird	Underperform → Neutral

Mostra tutto

Theravance Biopharma Inc Borsa (TBPH) Ultime notizie

Nov 20, 2024

Multiple System Atrophy Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma - The Globe and Mail

Nov 20, 2024

Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN

Nov 20, 2024

Theravance Biopharma to Present at Evercore HealthCONx Conference | TBPH Stock News - StockTitan

Nov 20, 2024

Nov 19, 2024

Madison Avenue Partners, LP Expands Stake in Theravance Biopharm - GuruFocus.com

Nov 14, 2024

Theravance Biopharma Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 14, 2024

Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75 - MarketBeat

Nov 14, 2024

Nov 13, 2024

Theravance Biopharma SVP Rhonda Farnum sells $36,000 in shares - Investing.com India

Nov 13, 2024

Theravance Biopharma SVP Rhonda Farnum sells $36,000 in shares By Investing.com - Investing.com Canada

Nov 13, 2024

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024

Theravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above Fifty Day Moving AverageTime to Sell? - MarketBeat

Nov 13, 2024